Mirum Pharmaceuticals Set to Unveil Phase 3 Data for Hepatitis Delta Treatment
Event summary
- Mirum Pharmaceuticals will host an investor call on September 28, 2026, to share topline results from the Phase 3 AZURE-1 study of brelovitug for chronic hepatitis delta virus (HDV).
- The call will also include 48-week data from the Phase 2b portion of the study.
- Brelovitug is a fully human monoclonal antibody in late-stage development for chronic HDV.
- Mirum's commercial portfolio includes treatments for rare liver and genetic diseases, such as LIVMARLI for Alagille syndrome and PFIC.
The big picture
Mirum Pharmaceuticals is poised to potentially expand its portfolio with a new treatment for chronic hepatitis delta, a rare and challenging condition. The upcoming data release could position the company as a key player in the rare disease sector, particularly if brelovitug demonstrates strong efficacy and safety. The strategic focus on rare liver and genetic diseases aligns with Mirum's existing commercial portfolio, which includes treatments for conditions like Alagille syndrome and PFIC.
What we're watching
- Clinical Efficacy
- How the topline results from the Phase 3 AZURE-1 study will impact the regulatory pathway for brelovitug.
- Market Positioning
- Whether Mirum can leverage positive data to strengthen its position in the rare disease space.
- Pipeline Progress
- The pace at which Mirum advances other pipeline candidates, such as volixibat and MRM-3379.
Related topics